Figure 4From: ABT-737 reverses the acquired radioresistance of breast cancer cells by targeting Bcl-2 and Bcl-xLABT-737 does not enhance the radiosensitivity of MDA-MB-231 cells. (A) Survival curves of the MDA-MB-231 cells with or without ABT-737 treatment following radiation. (B) Cell viability assays demonstrated that pre-treatment with ABT-737 does not increase radiation-induced cell death in the MDA-MB-231 cells. Columns, mean of three independent experiments; bars, SD.Back to article page